


# Author's Accepted Manuscript

Getting Products to Market: Understanding and Navigating the Regulatory Pathway

Andrew J. Riff, Adam B. Yanke, Brian J. Cole



PII: S1060-1872(16)30057-0  
DOI: <http://dx.doi.org/10.1053/j.otsm.2016.12.001>  
Reference: YOTSM50568

To appear in: *Operative Techniques in Sports Medicine*

Cite this article as: Andrew J. Riff, Adam B. Yanke and Brian J. Cole, Getting Products to Market: Understanding and Navigating the Regulatory Pathway, *Operative Techniques in Sports Medicine*, <http://dx.doi.org/10.1053/j.otsm.2016.12.001>

This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting galley proof before it is published in its final citable form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

## **Getting Products to Market: Understanding and Navigating the Regulatory Pathway**

Andrew J. Riff, MD, Adam B. Yanke, MD, MS, Brian J. Cole, MD, MBA

From: Rush University Medical Center

Corresponding Author: Adam Yanke, adam.yanke@rushortho.com

Mailing address: 1611 W. Harrison St., Suite 300, Chicago, IL 60612

### **ABSTRACT**

Orthobiologics are products that include growth factors, stem cells, and matrices, that are designed to alleviate symptoms and improve function in the setting of musculoskeletal injury. In the United States, biologics are regulated by the FDA's Center for Biologics Evaluation and Research (CBER). In 1997, the CBER established a tiered regulatory framework for management human cells, tissues, cellular, and tissue-based products (HCT/Ps) based on perceived risk. Products are separated into those exempted from regulation, those seen as low risk (section 361 products), and those seen as higher risk (section 351 products). The distinctions between section 361 and 351 products are primarily based upon the extent to which they are manipulated, used for a non-homologous purpose, combined with other products, and elicit a systemic effect. Higher risk products require more concrete data supporting product safety and efficacy derived from an investigational new drug (IND) application or independent device exemption (IDE). Under current regulations, blood products, including PRP, are exempt and

Download English Version:

<https://daneshyari.com/en/article/5710978>

Download Persian Version:

<https://daneshyari.com/article/5710978>

[Daneshyari.com](https://daneshyari.com)